ClinicalTrials.gg
Active, not recruitingNCT00840944ZomaTripUpdated Jul 28, 2023

A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height

A Phase 4 interventional study of somatropin and triptorelin in Idiopathic Short Stature, sponsored by Belgian Study Group for Pediatric Endocrinology. Active, not recruiting at 6 sites in Belgium. Open to participants aged 7 Years to 15 Years. Per ClinicalTrials.gov, last updated 2023-07-28.

Sponsored by Belgian Study Group for Pediatric Endocrinology · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2024, 2 years 10 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
7 Years to 15 Years
Sex
All
01

Study summary

Estrogens are responsible for the disappearance of growth cartilage in the long bones at the end of the pubertal growth spurt both in boys and in girls. It is therefore hypothesized that stopping pubertal development and hence estrogen production, will prolong and increase the pubertal growth spurt, especially when growth hormone is given concommitantly.

Boys in early puberty, with a bone age between 11 and 13 years and a predicted adult height below 163 cm or girls in early puberty with a bone age between 10 and 12 years and a predicted height under 151 cm will be treated with triptorelin 3.75 mg and Zomacton growth hormone for 4 years.

02

Conditions studied

  • Idiopathic Short Stature

Keywords

  • gonadotropin releasing hormone agonist
  • growth hormone
  • final height
  • bone density
  • puberty
03

In context

Lead sponsor

This is the only study on the registry with Belgian Study Group for Pediatric Endocrinology as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
7 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult height prediction below -2.5 SD : 151 cm for girls and 164 cm for boys based on the vlaamse groeicurve 2004 (vub.ac.be/groeicurven)
  • Pubertal: breast development at least M2 for girls and at least 4 ml of testicular volume for boys
  • Bone age >10 years but \< 12 years for girls and > 11 but \< 13 years for boys
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Adopted children ( different genetic background, lack of data on birth parameters and parents)
  • Bone dysplasia or sitting height/ total height > 2 SDS on standards by Gerver et al (see appendix)
  • Chronic use of
  • Previous growth promoting therapy such as GH, sex steroids, oxandrolone,
  • Known GH deficiency
  • Chronic infectious disease
  • Active rheumatic disease
  • Previously diagnosed or currently suspected
  • Sex steroid therapy
  • Diabetes mellitus
  • Renal insufficiency (serum creatinine > 1.5 mg/dl)
  • Hepatic disease ( liver test > 4 fold upper limit of normality)
  • Current congestive heart failure
  • Inability to follow the study protocol
  • Treatment with a non registered drug during the last 30 days before the moment of inclusion.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    ZOMATRIP

    GnRH agonist triptorelin plus somatropin

    Drug: somatropin · Drug: triptorelin

Interventions

  • somatropin 0.050 mg/kg/day

    Also known as: growth hormone, zomacton

  • triptorelin 3.75 mg each month

    Also known as: decapeptyl

06

What researchers measure

Primary outcomes

  1. height

    Difference between predicted height at start of treatment and adult height

    Time frame: 6 - 8 years

Secondary outcomes

  1. bone density

    Bone density SDS measured by DEXA

    Time frame: 6 - 8 years

07

Study locations

6 sites
  • Antwerp University Hospital
    Edegem, Antwerpen 2650, Belgium
  • Jessah Ziekenhuis
    Hasselt, Limburg 3000, Belgium
  • Kinderziekenhuis UGent
    Gent, Oost Vlaanderen 9000, Belgium
  • Hopital Universitaire Reine Fabiola (HUDERF)
    Brussels, 1050, Belgium
  • Kinderziekenhuis UZ Brussel
    Brussel, 1090, Belgium
  • CHU ND-des Bruyères
    Liege, 4030, Belgium
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Jan 2024 and a completion of Apr 2024. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2009
First posted
Feb 11, 2009
Start
Jan 2008
Primary completionEst.
Jan 2024
CompletionEst.
Apr 2024
Last update
Jul 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00840944
Lead sponsor
Belgian Study Group for Pediatric Endocrinology
Responsible party
Hilde Dotremont (MD, Belgian Study Group for Pediatric Endocrinology) — Principal investigator
First posted
Feb 11, 2009
Start date
Jan 2008
Primary completion
Jan 2024 (estimated)
Completion
Apr 2024 (estimated)
Last update
Jul 28, 2023

Study contacts

Hilde Dotremont, MD
principal investigator · BSGPE

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion